# Cross-ancestry analysis identifies genes associated with obesity risk and protection

Deepro Banerjee[1,2] and Santhosh Girirajan[1,2,3]

1.  Bioinformatics and Genomics Graduate Program, The Huck Institute of the Life Sciences, University Park, PA 16802
2.  Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA 16802
3.  Department of Anthropology, Pennsylvania State University, University Park, PA 16802

Correspondence:
Santhosh Girirajan
205A Life Sciences Building
Pennsylvania State University
University Park, PA 16802
E-mail: sxg47@psu.edu

**ABSTRACT**

Gene discoveries in obesity have largely been based on European cohorts, leading to an ancestral bias, that limits their generalizability across populations. We performed a gene-based rare variant association study of 721,941 individuals and identified 116 novel BMI-associated genes with consistent effects across ancestries, including 50 risk-conferring and 66 protective genes against obesity. Protective genes such as *DCUN1D3* and *NEUROD6* had effect sizes comparable to high-risk genes such as *MC4R* and *BSN*, and nearly twice that of known protective genes such as *GPR75*, which, along with five other genes, showed strong European bias. Notably, 82 of the 116 genes showed functional relevance to obesity including adiposity, energy homeostasis, and glucose metabolism. While polygenic risks or an obesogenic lifestyle amplified the effect of 15 genes on BMI, including the combination of low physical activity and *MACROD1*, 23 genes including *VIRMA*, *AQP3*, and *PML* retained protective effects even at high polygenic scores. Our findings provide further insights into the genetic basis of obesity that is conserved across ancestries and their interactions with obesogenic factors.

**MAIN**

Obesity is a complex, heritable disorder with significant global impact, contributing to numerous comorbidities and public health challenges[1]. It is influenced by a combination of genetic and lifestyle factors[2,3], yet the genetic component underlying the etiology of obesity remains a key area of investigation. While large-scale studies have identified roles for common variants[4], including significant effects of polygenic risk scores (PGS)[5], and rare protein-truncating variants in obesity risk genes such as *MC4R* and *BSN*[6–9], as well as protective genes such as *GPR75*[9], these studies have predominantly focused on populations of European ancestry. Non-European populations are often underrepresented or included only for replication purposes[6–8]. This lack of diversity in genetic studies has resulted in two major issues: a bias in gene discovery towards a specific ancestry, and a limited ability to detect associations that may be significant in non-Europeans but lack statistical power in predominantly European cohorts[10]. *For example*, clinically significant variants in *APOL1* and *PCSK9* associated with kidney disease and low LDL cholesterol, respectively, were both discovered in populations of African ancestry[11,12]. The consequences of this bias extend beyond gene discovery, affecting the generalizability of obesity-related findings to the broader global population and potentially limiting the effectiveness of precision medicine approaches[13].

Here, we conducted a rare variant association analysis of body-mass index (BMI) using genetic and phenotypic data from 721,941 adults of diverse ancestries, leveraging cohorts from the UK Biobank (UKB) and the All of Us (AoU) initiative. Unlike previous rare variant association studies of BMI that prioritized European populations for discovery and non-Europeans for replication, we adopted a discovery approach in non-European populations as well. Combining statistics across populations, we identified 121 genes, 116 of which have not been previously linked to BMI in the context of rare variants, that showed consistent risk-conferring and protective effects across ancestries. Our findings also revealed a strong European bias in previously identified obesity genes, with effect sizes varying significantly in non-European populations. These disparities highlight the critical need for more inclusive genomic studies to ensure equitable obesity interventions.

**RESULTS**

**Cross-ancestry analysis to identify BMI-associated genes**

We analyzed genetic and electronic health record data of 721,941 adults from the UKB and AoU

cohorts representing six ancestries[14,15]. We divided the cohorts into five populations, each with at

least 50,000 individuals (**Table 1**). We used REGENIE v3.3[16] to perform gene-burden

association tests by collapsing ultra-rare (minor allele frequency <0.1%) protein truncating

variants (PTVs, defined as predicted loss of function or deleterious missense variants) for each

gene and measuring their effect on BMI for each independent population. Using Bonferroni

multiple testing correction (P<8.34 x $10^{-7}$, 20,000 genes, and three variant collapsing models, see

**Methods**) and sample size (N≥20) thresholds, we identified a total of 11 BMI-associated genes

from the UKB British (*MC4R*, *PCSK1*, *DIDO1*, *BSN*, *UBR2*, *ATP5PO*, *APBA1*, *SLC12A5*, and

*ATP13A1*) and AoU European (*MC4R*, *HECTD4* and *YLPM1*) populations, while no significant

genes were found in the UKB non-British, AoU African, or AoU mixed populations, potentially

due to insufficient statistical power to detect any association (**Supplementary Table 1**).

Therefore, to identify genetic associations that are consistent across populations, we performed

random-effect inverse variance weighted meta-analysis[17] by aggregating summary statistics from

each population into European (UKB British and AoU European populations), non-European

(UKB non-British, AoU African, and AoU mixed populations), and combined (all five

populations) results. Gene-burden associations that passed multiple testing correction in either

the European or non-European meta-analysis, as well as in the combined result, were considered

to be significant gene-BMI associations across ancestries. In contrast to previous cross-ancestry

studies of BMI where European meta-analysis was typically used for discovery and non-

European analysis for replication, we did not define a single discovery population. Instead, we

applied the same discovery approach in both populations, such that discoveries in Europeans

were replicated in non-Europeans, and vice versa. This strategy allowed us to detect association

signals for BMI in both populations, with consistent effect sizes.

Using our cross-ancestry approach, we discovered 116 novel genes (50 associated with

increased BMI and 66 with decreased BMI), along with five genes (*APBA1*, *BSN*, *MC4R*,

*ROBO1*, and *UBR2*) that were previously identified in rare-variant studies on BMI[6,7,9,18] (**Fig. 1**,

**Supplementary Tables 2, 3 and 4**). We found that 28 out of the 33 known BMI-associated

genes did not pass the exome-wide significance threshold, including six genes (*GPR75*, *PTPRG*,

*SPARC*, *RAB21*, *ATP13A1,* and *DIDO1*) that were only significant in Europeans but not in the

combined meta-analysis (**Supplementary Table 5**). This result is consistent with a recent study

by Zhao and colleagues where the association of *ATP13A1* with BMI did not replicate in a non-

European cohort[7]. In contrast, we found that *GIPR* showed a significant effect in non-Europeans

($\beta$=-1.12 kg/m$^2$, 95% CI: -1.54, -0.70, *P*=1.67x10$^{-7}$) but not in Europeans ($\beta$=-0.44 kg/m$^2$, 95%

CI: -0.89, 0.05, *P*=0.09). We did not find significance for some genes such as *KSR2*, *ZFHX3,*

and *RAPGEF3,* where previous associations were driven by specific protein-altering variants[6],

while for other genes such as *ANO4*, *DPP9,* and *TOX4* cohort-specific biases may have driven

previous associations. *For instance*, Zhao and colleagues failed to replicate the association of

*TOX4* in a non-European cohort[7] (**Supplementary Fig. 1, Supplementary Table 5**).

**Table 1**: Cohort and population statistics analyzed in this study.

| Population | European | Non-European | Combined |
|---|---|---|---|
| UKB British | 419,228 | | 419,228 |
| UKB non-British (includes African, East Asian, South Asian ancestries) | | 68,070 | 68,070 |
| AoU European | 127,644 | | 127,644 |
| AoU African | | 54,865 | 54,865 |
| AoU Mixed (includes Latino/admixed American, East Asian, South Asian and Middle Eastern ancestries) | | 52,134 | 52,134 |
| Meta population (N) | **546,872** | **175,069** | **721,941** |

In our discovered genes, *MYOG* ($\beta$=3.87 kg/m$^2$, 95% CI: 3.14, 4.6, *P*=0), *ZFC3H1*

($\beta$=1.78 kg/m$^2$, 95% CI: 1.53, 2.02, *P*=0), and *TMEM229A* ($\beta$=1.77 kg/m$^2$, 95% CI: 1.47, 2.07,

*P*=0) contributed to the highest increase in BMI, with effect sizes comparable to *MC4R*, *BSN*,

and *UBR2*. In fact, we identified 40 such high-effect genes, including 24 BMI increasing and 16

BMI decreasing, which contributed to at least 1 kg/m$^2$ change in BMI (**Fig. 1, Supplementary**

**Table 4**). The effect sizes of several BMI-increasing genes, including *MACROD1*, *ICE1*, *ADNP*,

*NACC2,* and *LPCAT4,* were robust and showed minimal variability across ancestries

(interpopulation variance, $V_\beta$<0.15) (**Fig. 2, Supplementary Table 6**). Similarly, BMI-

decreasing genes such as *B3GNT2* ($V_\beta$=0.06), *SNAP29* ($V_\beta$=0.10), *VIRMA* ($V_\beta$=0.13)*, and CCT7*

($V_\beta$=0.13) showed more consistent effect sizes than previously reported protective genes,

including *GPR75* ($V_\beta$=1.06) and *GPR151* ($V_\beta$=0.49) (**Fig. 2, Supplementary Table 6**). Further,

the absolute effect sizes of BMI-decreasing genes, *DCUN1D3* ($\beta$=-3.84 kg/m$^2$, 95% CI: -4.6, -

3.09, $P$=0), *NEUROD6* ($\beta$=-3.02 kg/m$^2$, 95% CI: -4.16, -1.89, $P$=1.8x10$^{-7}$), and *SH3GL2* ($\beta$=-

2.34 kg/m$^2$, 95% CI: -3.05, -1.63, $P$=1.16x10$^{-10}$) were comparable to those of *MC4R* and *BSN*.

These results highlight the robustness of our cross-ancestry gene discovery approach.

**Fig. 1**: **Monogenic genes contributing to at least 1.5 kg/m$^2$ difference in BMI across**
**ancestries**. Effect sizes along with 95% confidence intervals (CI) and significance values (*P*
value) in European, non-European, and combined meta-analysis for high-effect (>1.5 kg/m$^2$)
genes associated with (**a**) increased and (**b**) decreased BMI are shown. Three variant collapsing
models were tested for each gene and the one with the lowest *P* value in the combined meta-
analysis is shown here. † indicates known BMI genes. Data for all genes contributing to change
in BMI (including those contributing to >1 kg/m$^2$) are provided in **Supplementary Table 4**.

| Genes | Beta (95% CI) | *P* value |
|---|---|---|
| GPR75 | -0.84 (-2.00, 0.32) | $1.57\times10^{-01}$ |
| | -1.47 (-1.69, -1.25) | 0 |
| | -1.11 (-1.81, -0.42) | $1.64\times10^{-03}$ |
| GIPR | -1.12 (-1.54, -0.70) | $1.65\times10^{-07}$ |
| | -0.44 (-0.92, 0.05) | $8.02\times10^{-02}$ |
| | -0.92 (-1.34, -0.51) | $1.29\times10^{-05}$ |
| DPP9 | -0.67 (-2.38, 1.03) | $4.40\times10^{-01}$ |
| | -1.29 (-2.53, -0.06) | $4.06\times10^{-02}$ |
| | -0.82 (-1.94, 0.31) | $1.55\times10^{-01}$ |
| GPR151 | -0.27 (-0.77, 0.23) | $2.85\times10^{-01}$ |
| | -0.11 (-0.33, 0.12) | $3.60\times10^{-01}$ |
| | -0.24 (-0.57, 0.09) | $1.51\times10^{-01}$ |
| ZFHX3 | 0.07 (-0.66, 0.81) | $8.44\times10^{-01}$ |
| | 0.81 (-0.46, 2.08) | $2.13\times10^{-01}$ |
| | 0.23 (-0.39, 0.86) | $4.59\times10^{-01}$ |
| ANKRD27 | 0.71 (0.63, 0.79) | 0 |
| | -0.05 (-0.07, -0.03) | $1.78\times10^{-07}$ |
| | 0.33 (-0.05, 0.71) | $8.47\times10^{-02}$ |
| RAPGEF3 | 0.65 (0.04, 1.26) | $3.62\times10^{-02}$ |
| | 0.09 (-0.33, 0.51) | $6.62\times10^{-01}$ |
| | 0.41 (-0.04, 0.85) | $7.32\times10^{-02}$ |
| ATP13A1 | 0.76 (0.27, 1.25) | $2.28\times10^{-03}$ |
| | 0.40 (0.32, 0.48) | 0 |
| | 0.64 (0.31, 0.97) | $1.42\times10^{-04}$ |
| KSR2 | 1.25 (-3.47, 5.98) | $6.03\times10^{-01}$ |
| | 0.80 (-1.75, 3.34) | $5.41\times10^{-01}$ |
| | 1.08 (-1.69, 3.86) | $4.44\times10^{-01}$ |
| SPARC | 0.92 (-0.47, 2.30) | $1.95\times10^{-01}$ |
| | 1.68 (1.28, 2.09) | $2.22\times10^{-16}$ |
| | 1.24 (0.39, 2.08) | $4.19\times10^{-03}$ |
| PTPRG | 1.50 (0.53, 2.48) | $2.39\times10^{-03}$ |
| | 1.05 (-0.06, 2.16) | $6.33\times10^{-02}$ |
| | 1.27 (0.61, 1.93) | $1.61\times10^{-04}$ |
| RAB21 | 2.22 (-4.92, 9.35) | $5.43\times10^{-01}$ |
| | 1.44 (1.31, 1.56) | 0 |
| | 1.75 (-1.46, 4.96) | $2.86\times10^{-01}$ |
| ANO4 | 2.34 (0.21, 4.47) | $3.10\times10^{-02}$ |
| | 1.44 (0.70, 2.18) | $1.44\times10^{-04}$ |
| | 1.87 (0.71, 3.04) | $1.64\times10^{-03}$ |
| TOX4 | 2.06 (-0.16, 4.29) | $6.93\times10^{-02}$ |
| | 3.89 (0.08, 7.71) | $4.56\times10^{-02}$ |
| | 2.85 (0.91, 4.79) | $4.02\times10^{-03}$ |
| DIDO1 | 3.22 (-1.14, 7.58) | $1.47\times10^{-01}$ |
| | 2.82 (2.04, 3.61) | $1.59\times10^{-12}$ |
| | 3.03 (0.80, 5.25) | $7.70\times10^{-03}$ |

Non-European meta
European meta
Combined meta

**Supplementary Fig. 1**: **Effect of previously identified BMI-associated genes across ancestries**. Effect sizes along with 95% confidence intervals (CI) and significance values (*P* value) in European, non-European, and combined meta-analysis for genes previously associated with BMI are shown. Three variant collapsing models were tested for each gene and the one with the lowest *P* value in the combined meta-analysis is shown here. Extended data are available in **Supplementary Table 5**.

**Fig. 2**: **Interpopulation variance of known and discovered BMI genes**. Interpopulation variance plot with effect sizes along x-axis and variance of effect sizes across populations along y-axis of previously identified (in red diamond) and discovered (in purple dots) BMI genes are shown. Three variant collapsing models were tested for each gene and the one with the lowest *P* value in the combined meta-analysis is shown here. Extended data are available in **Supplementary Table 6**.

**Cardiometabolic profile of carriers of PTVs in BMI-associated genes**

We next examined whether PTV carriers in the BMI-associated genes were enriched across different obesity categories, namely, underweight/normal (BMI<25), overweight (25≤BMI<30), obese (30≤BMI<40), and severely obese (BMI≥40). Of the BMI-increasing genes, PTV carriers in 35 genes, including *NCOR1* (OR=1.28, 95% CI: 1.04, 1.58, *P*=0.02), *SEC24B* (OR=1.46, 95% CI: 1.04, 2.04, *P*=0.02), *ADNP* (OR=1.77, 95% CI: 1.15, 2.7, *P*=0.007), and *ANGPT2* (OR=1.62, 95% CI: 1.08, 2.42, *P*=0.01), showed higher odds for obesity, while PTV carriers in 22 genes, including *MACROD1* (OR=2.11, 95% CI: 1.31, 3.25, *P*=0.002), *ICE1* (OR=1.74, 95% CI: 1.06, 2.73, *P*=0.01), and *MYOG* (OR=7.47, 95% CI: 1.73, 25.21, *P*=0.004), showed higher odds for severe obesity (**Fig. 3a, Supplementary Fig. 2, Supplementary Table 7**). Of the BMI-

decreasing genes, PTV carriers in 15 genes, including *NEUROD6* (OR=2.78, 95% CI: 1.05, 7.61,

*P*=0.03), *DCUN1D3* (OR=2.49, 95% CI: 1.00, 6.22, *P*=0.04), *SH3GL2* (OR=2.4, 95% CI: 1.49,

3.87, *P*=0.0001), and *VIRMA* (OR=1.47, 95% CI: 1.11, 1.94, *P*=0.006), were more likely to be

underweight or normal than individuals without PTVs in those genes (**Fig. 3a, Supplementary**

**Fig. 2, Supplementary Table 7**). Further, individuals with PTVs in *VIRMA* (OR=0.51, 95% CI:

0.35, 0.73, *P*=7.18x10$^{-5}$), *RABEP1* (OR=0.53, 95% CI: 0.32, 0.85, *P*=0.005), *CDK7* (OR=0.67,

95% CI: 0.46, 0.96, *P*=0.03), and *P2RY1* (OR=0.44, 95% CI: 0.18, 0.96, *P*=0.03) were less likely

to be obese, while individuals with PTVs in *AQP3* (OR=0.13, 95% CI: 0.003, 0.76, *P*=0.01) and

*TSPAN4* (OR=0.46, 95% CI: 0.22, 0.86, *P*=0.01) were also less likely to be severely obese. This

analysis confirmed obesity risk and protective effects of the BMI-associated genes discovered in

our study.

We also found significantly altered risks for 15 obesity-related comorbidities in carriers

of PTVs in both obesity-risk conferring and protective genes compared to non-carriers (**Fig. 3b,**

**Supplementary Table 8**). *For instance*, individuals with PTVs in *LPGAT1* showed higher risks

for 5 out of 15 comorbidities, including aortic valve stenosis (OR=4.05, 95% CI: 1.46, 9.07,

*P*=0.005), heart failure (OR=2.33, 95% CI: 1.17, 4.21, *P*=0.01), and knee osteoarthritis

(OR=2.27, 95% CI: 1.40, 3.55, *P*=0.0006). Notably, *TMEM229A*, despite conferring obesity

risk, showed depletion for heart failure phenotype in carriers (OR=0, 95% CI: 0, 0.93, *P*=0.03).

Among the obesity protective genes, PTV carriers in *VIRMA* and *SCFD1* showed reduced risk

for most of the tested cardiometabolic phenotypes, including significant depletion for venous

thromboembolism (OR=0, 95% CI: 0, 0.65, *P*=0.008) and hypertension (OR=0.49, 95% CI:

0.28, 0.85, *P*=0.007), respectively. Further, PTV carriers in the BMI-decreasing *PANK1* and

*P2RY1* exhibited an increased risk for type 2 diabetes (OR=1.74, 95% CI: 1.16, 2.54, *P*=0.005)

and heart failure (OR=2.82, 95% CI: 0.87, 7.11, *P*=0.04), respectively. While obesity risk-

conferring genes typically associated with worse cardiometabolic profiles and protective genes

with better profiles, notable exceptions were observed where obesity protective genes conferred

risk and risk genes were protective for certain cardiometabolic phenotypes.

**Fig. 3**: **Enrichment of obesity and cardiometabolic comorbidities in PTV carriers of the discovered BMI associated genes**. (**a**) *Top*: Proportion of PTV carriers within the obesity clinical categories (underweight or normal, overweight, obese, and severely obese) that led to at least 1.5 kg/m$^2$ increase (risk) or decrease (protective) in BMI. *Bottom*: Odds ratio of obesity clinical categories in carriers compared to non-carriers. *$P<0.05$. Extended data with the odds ratios, 95% confidence intervals and exact *P* values are available in **Supplementary Table 7. (b)** Odds ratio for obesity-related comorbidities in PTV carriers of risk or protective genes compared to non-carriers. *$P<0.05$, **$P<0.01$, ***$P<0.001$. Extended data with the odds ratios, 95% confidence intervals and exact *P* values are available in **Supplementary Table 8.**

Supplementary Fig. 2: **Enrichment in obesity clinical categories for BMI-associated genes**.
Proportion of PTV carriers in obesity clinical categories that led to between 1 to 1.5 kg/m$^2$
increase (risk) or decrease (protective) in BMI. The odds ratio of being underweight or normal,
overweight, obese, and severely obese among carriers compared to non-carriers is also shown in
the table below (*$P$<0.05). All data with the odds ratio, 95% confidence intervals, and exact $P$
values are available in **Supplementary Table 7**.

**Functional analysis of obesity-associated genes**

We evaluated the impact of natural variation in plasma protein levels of the discovered genes on

BMI of individuals from the UK Biobank, irrespective of their PTV carrier status. Among the

discovered BMI-associated genes, six had plasma protein measurements from approximately

50,000 individuals. We constructed linear models using protein expression as the independent

variable and BMI, corrected for covariates, as the dependent variable. All six proteins had

significant model coefficients, with DNER having the highest absolute effect on BMI (**Fig. 4a,**

**Supplementary Table 9**), consistent with the association of *DNER* PTVs with severe obesity.

Protein levels of FGF2 (β=0.21, $P$=3.87 x 10$^{-14}$) and GLOD4 (β=0.79, $P$=7.02 x 10$^{-53}$)

associated with increased BMI, supporting the observation that disruption of these genes leads to

a decrease in BMI (**Supplementary Fig. 3**). Interestingly, increased CD27 and ROBO1 levels

associated with increased BMI, contrary to the expected effect from PTVs in these genes, which

resulted in increased BMI. This suggests a complex relationship between protein expression of

these genes and their effect on BMI. Our results show that natural variation in protein expression

levels, potentially due to other common or rare non-coding variants, of the genes identified in

our study are associated with BMI.

We next assessed whether the 116 novel genes identified in our study had been previously linked to obesity or related pathways using genetic and functional approaches beyond rare variant association studies. Nineteen genes, including *MACROD1*, *VIRMA*, and *RABEP1*, had common variant signals associated with BMI recorded in the GWAS catalog[19] (**Supplementary Table 10 and 11**). We also queried the Common Metabolic Diseases Knowledge Portal[20], which aggregates and scores genotype-phenotype relationships (Human Genetic Evidence, or HuGE scores[21]) based on evidence from both rare and common variant association studies. This analysis identified 16 more genes, including *LAMB2*, *FARP2*, *CELSR3*, and *ANGPT2*, that showed strong associations (HuGE score≥10) with BMI or related phenotypes such as waist-hip ratio adjusted BMI or fasting insulin-adjusted BMI (see **Supplementary Table 10 and 11**).

We further investigated the functional effects of knocking out obesity-associated genes using data from the International Mouse Phenotyping Consortium[22] and previous studies in mouse models. We found that 15 of our novel genes (five associated with risk and ten protective against obesity) exhibited directionally consistent obesity-related phenotypes in mice, such as changes in total body fat, lean mass, and glucose tolerance (**Table 2**). Among the obesity risk-conferring genes, we found impaired glucose tolerance, and increased weight gain in mouse models of *Lonrf2*[22], *Ncor1*[23], and *Gabra5*[24], respectively. Mouse studies further highlighted the involvement of these genes in obesity-related processes such as thermogenesis (*Fgf2*[25] and *Gabra5*[24]), adipogenesis (*Ncor1*[23]), glucose metabolism (*Abca1*[26]), fatty acid metabolism (*Pml*[27]), and skeletal muscle metabolism (*Mipep*[28]). We also found direct evidence of protective effects from homozygous knockouts of *Aqp3*, *Kctd7*, and *Fgf2* in mice, resulting in increased lean mass, reduced total body fat, and resistance to obesity with a high-fat diet, respectively (**Table 2**). In addition, *Dcun1d3* homozygous knockout mice showed a significant reduction in total body fat, increased lean mass, and improved glucose tolerance. Finally, we performed a systematic literature review and found evidence for 71 genes with functional roles in obesity, including *MMP3*, *SLC25A1*, *CYP3A5*, *APMAP*, and *UCP3* (**Fig. 4b, Supplementary Table 12**). Overall, we found evidence linking 82 out of the 116 discovered genes to obesity or related phenotypes, based on previous association studies, plasma proteomics, and mouse models (**Fig. 4b, Supplementary Table 11**).

**Table 2**: List of mouse models of BMI-associated genes showing obesity-related phenotypes.

| Risk gene | Evidence from mouse models |
| --- | --- |
| *ABCA1* | Increased weight gain in adipocyte specific *Abca1$^{-ad/-ad}$* KO mouse when fed a high fat diet[26] |
| *GABRA5* | Increased weight gain in chemogenetically inhibited (by clozapine N-oxide) mouse when fed a high fat diet[24] |
| *NCOR1* | Increased weight gain in adipocyte specific *NCoR$^{fl/fl}$aP2-Cre$^{+/-}$* KO mouse when fed a high fat diet[23] |
| *LONRF2* | Impaired glucose tolerance observed in *Lonrf2$^{em2(IMPC)H}$* homozygous KO mouse model |
| *ANGPT2* | Protection from high fat diet induced obesity in adipose tissue specific overexpressed (by doxycycline) mouse[29] |

| Protective gene | Evidence from mouse models |
| --- | --- |
| *DCUN1D3* | Decreased total body fat mass, increased lean body mass and improved glucose tolerance observed in *Dcun1d3$^{em1(IMPC)Wtsi}$* homozygous KO mouse |
| *AQP3* | Increased lean body mass observed in *Aqp3$^{tm2b(EUCOMM)Wtsi}$* homozygous KO mouse |
| *SNAP29* | Increased lean body mass observed in *Snap29$^{tm1a(EUCOMM)Wtsi}$* heterozygous KO mouse |
| *KCTD7* | Decreased total body fat amount observed in *Kctd7$^{em2(IMPC)Bay}$* homozygous KO mouse model |
| *FGF2* | Protection from high fat diet induced obesity in *Fgf2$^{-/-}$* homozygous KO mouse[25] |
| *MTFP1* | Protection from high fat diet induced obesity in liver specific *Alb-Cre$^{tg/+}$Mtfp1$^{LoxP/LoxP}$* KO mouse[30] |
| *SETX* | Improved glucose tolerance observed in *Setx$^{tm1b(EUCOMM)Wtsi}$* homozygous KO mouse |
| *MIPEP* | Protection from high fat diet induced obesity in adipocyte specific *miPEP$^{flox/flox}$Adiponectin-Cre$^{+/-}$* KO mouse[28] |
| *AHNAK* | Improved glucose tolerance observed in *Ahnak$^{tm1b(KOMP)Mbp}$* heterozygous KO mouse |
| *PML* | Protection from western diet induced obesity in *Pml$^{-/-}$* mouse[27] |

**Fig. 4**: **Functional validation of BMI associated genes**. (**a**) Model coefficients, with 95 % CI and *P* value, of a linear model constructed using plasma protein expression values of BMI-associated genes as independent variable and BMI as the dependent variable. Data with exact *P* values, model coefficients and 95% confidence interval are available in **Supplementary Table 9. (b**) Upset plot of evidence for a role of the identified BMI-associated genes in obesity-related functions and phenotypes. The bars represent the number of genes with functional relevance found from the respective study, which is represented by the dots. RVAS, Rare variant association study; IMPC, International mouse phenotypic consortium; GWAS: Genome wide association study; CMDKP: Common metabolic diseases knowledge portal.

**Supplementary Fig. 3: Relationship between plasma protein levels and BMI**. Association of the plasma protein levels with BMI in the population (grey scatters) and the PTV carriers (red scatters) for (**a**) DNER, (**b**) FGF2, (**c**) GLOD4, (**d**) CD27, (**e**) ROBO1, (**f**) MMP3.

**Interactions of obesity-associated genes with polygenic risk and lifestyle factors**

We assessed how PGS modulated the effect of the identified genes on BMI (**Supplementary Fig. 4a**). We used linear regression to test multiplicative interactions between PGS and each disrupted gene towards changes in BMI. We identified four scenarios where PGS contributed to the variability in BMI among individuals with PTVs in the same gene (**Fig. 5a and b, Supplementary Fig. 4b**). In the *first* scenario, BMI was synergistically increased by both PGS and PTVs in risk genes, leading to more severe obesity. *For example*, individuals with PTVs in *TSFM*, *LPGAT1*, *FAM171A2*, *ICE1*, *TNK2,* and *TPRX1* and eight other genes showed a synergistic increase in BMI in concert with PGS. This pattern was more evident in carriers of *BSN* PTVs where a non-additive increase in BMI was observed across PGS quintiles (**Fig. 5c**). *Second*, the combined effect of PGS and PTVs in five risk genes, including *UBR2* and *PAM*, was much lower than their expected additive effects on BMI (**Fig. 5c**). *Third*, PGS was found to override the effect of six protective genes such as *SH3GL2* and *APMAP*, and individuals with high PGS still showed increased BMI despite carrying PTVs in BMI-decreasing genes (**Fig. 5c**). In the *fourth* scenario, we noted that 23 protective genes override the strong obesity risk-conferring effect of PGS, and individuals remain protected despite carrying high polygenic risk for obesity. *For example*, the effect of PGS in the highest quintile among carriers of PTVs in *VIRMA* was 2.53 kg/m$^2$ less than in non-carriers (**Fig. 5c**). We did not identify non-additive effects of PGS on other disrupted genes such as *MC4R*, *APBA1* and *ROBO1*, consistent with previous reports[7,9] (**Supplementary Table 13**).

We next investigated the effect of obesity-inducing lifestyle factors on the BMI of PTV carriers after controlling for PGS. We found that the effects of PTVs in *MACROD1* and *VIRMA* was modulated by the degree of physical activity of individuals. In particular, individuals carrying *MACROD1* PTVs with low physical activity (UKB) or bad physical health (AoU) had a higher BMI compared to non-carriers, in both UKB and AoU cohorts (**Fig. 5d, Supplementary Table 14**). On the other hand, the protective effect of *VIRMA* was more pronounced in individuals with low physical activity in the UKB cohort but was diminished in individuals self-reported to be in bad physical health in the AoU cohort (**Supplementary Fig. 4c, Supplementary Table 14**). This observation could be attributed to differences in how lifestyle factors are measured across UKB and AoU, or other cohort-specific factors. We also identified associations for carriers of *MC4R*, *TNK2,* and *GADL1* PTVs with diet, sleep, and sedentary

312  lifestyle factors, respectively, in UKB (**Supplementary Table 15**), but these associations could

313  not be tested in AoU due to the lack of comparable data. Our results underscore the influence of

314  PGS and obesogenic factors towards the effect conferred by obesity risk and protective genes.

325 interaction scenarios. (**d**) BMI distribution of *MACROD1* PTV carriers compared to non-carriers,
326 stratified by their physical activity levels in UKB (left) and AoU (right) cohorts.
327

**Supplementary Fig. 4**: **Effect of obesity-associated genes modulated by polygenic and**
**obesogenic risk factors**. (**a**) BMI distribution of PTV carriers in high-effect obesity genes. (**b**)
Interaction plots depicting the different scenarios through which PGS modulates the BMI of

individuals with PTVs in the discovered genes. (**c**) BMI distribution of carriers of PTVs in
*VIRMA* compared to non-carriers stratified by their physical activity levels in UKB (left) and
AoU (right) cohorts.
335

**DISCUSSION**

Here, we discovered 116 genes with consistent effects on BMI across ancestries and provide

accurate estimates of effect sizes for known obesity genes. By using genetic data from both

European and non-European populations, we uncovered gene-discovery biases present in

previous studies particularly in genes such as *DIDO1*, *SPARC*, and *RAB21* that showed

significant associations only in Europeans. Typically, protective obesity genes have been more

challenging to identify than risk genes, but three notable ones, *GPR75*, *GPR151*, and *GIPR*, have

emerged more recently through rare variant association studies[6,9,31]. However, our findings

suggest that these genes may also be influenced by ancestral biases, with variable effect sizes

across populations, which could impact their potential as therapeutic targets for obesity. In

contrast to previous studies, we identified genes with consistent effects across ancestries and

functional evidence, such as mouse knockout models for these genes, confirm their role in

obesity-related pathways. These findings emphasize the value of a cross-ancestry analysis, which

enabled the discovery of several novel genes with effect sizes comparable to canonical obesity

genes such as *MC4R* and *BSN*.

A significant finding from our study was the identification of 66 protective genes, some

of which exhibit effect sizes more than twice that of known protective genes. Notably,

*DCUN1D3* showed the highest effect size, with PTVs in these genes leading to approximately

3.8 kg/m$^2$ decrease in BMI. This gene is highly expressed in adipocytes, and *Dcun1d3* knockout

mice showed reduced fat body mass, increased lean body mass and improved glucose

tolerance[22]. *DCUN1D3* encodes a protein involved in neddylation, a post translation

modification that attaches a small ubiquitin-like molecule, NEDD8, to substrate proteins, altering

their properties[32,33]. Disruption of neddylation has been linked to impaired energy metabolism

and age-related metabolic disorders[34,35]. While the mechanisms by which *DCUN1D3* might

influence these pathways or diseases are unclear, our findings suggest that its inhibition could be

a therapeutic target for obesity. Similarly, *VIRMA* consistently led to decreased BMI, is

supported by evidence from nearby common variant signals[19], and individuals with PTVs in this

gene displayed improved cardiometabolic health. Two other protective genes, *AQP3* and *FGF2*,

not only showed evidence from mouse models for obesity protection but also have well-

established functional roles in glycerol metabolism[36] and thermogenesis[25]. Currently,

pharmacological inhibitors or negative modulators, such as Bisacodyl and Pentosan polysulfate,

exist for *AQP3* and *FGF2*; however, they are used as a laxative and for bladder pain,

respectively[37]. We also found that Setmelanotide, the *MC4R* agonist used for weight loss, is also

an agonist of *ANGPT2*, an obesity risk gene discovered in our study, with evidence from mouse

models demonstrating its role in body weight regulation[29,38]. Thus, our discoveries provide

avenues for repurposing existing drugs or devising new ones to alleviate obesity risk.

372           While polygenic risks have been found to additively influence rare variant risk for

obesity[9], a recent study showed *BSN* and PGS interact non-additively. In addition to

recapitulating the effect between *BSN* and PGS, we found synergistic effects of PGS on other

genes, such as *TSFM*, *LPGAT1*, and *FAM171A2*, as well. Further, synergistic interactions

between obesity causing risk factors can also exacerbate the risk of severe obesity and its

associated morbidities. *For instance*, carriers of PTVs in *MACROD1*, an obesity risk gene,

showed significantly higher BMI when they were physically inactive compared to carriers who

were active. While previous studies have shown the adverse effect of lifestyle factors on

common variants associated with BMI[2], we provide evidence that rare variant risk can be

modulated by obesogenic factors. Notably, carriers of PTVs in protective genes such as *VIRMA*

and *PI4KB*, remained protected despite having high PGS, highlighting the complex patterns of

interactions between specific obesity genes and PGS. Understanding these genetic and gene-

environment interactions could be key to developing more effective interventions, where lifestyle

changes may mitigate genetic risk in high-risk individuals, and protective variants might offer

resilience against obesogenic factors. Overall, using a multi-ancestry approach, we provide a

more comprehensive view of obesity genetics, identifying novel genes, refining the effects of

known genes, and demonstrating the importance of including diverse populations in genetic

studies.

**METHODS**

**Variant quality control, filtering, and annotation**

We analyzed whole exome sequencing data of 469,835 individuals from the UK Biobank (UKB)

cohort, available as multi-sample project variant call format (pVCF) files in the UKB Research

Analysis Platform (RAP). The sequencing method and preparation of the pVCF files have been

previously described[39]. Using the Hail[40] platform on DNANexus, we first split multi-allelic

records, and then filtered to retain rare variants with intracohort frequency <0.001. These

variants were annotated using variant effect predictor[41] (VEP v109) and dbNSFP v4[42] to identify

the predicted variant effects on gene transcripts. All variants within protein coding genes in the

autosomes with a call rate of 50% were used for subsequent analysis. We then annotated each

variant based on their most deleterious functional impact on the transcript into three categories,

from the most harmful to the least harmful, as follows: (1) Loss of function or "lof", which

included frameshift, stop gained, splice acceptor, and splice donor VEP annotations, (2)

"missense strict", which included missense variants predicted to be deleterious by nine

deleteriousness prediction tools (SIFT[43], LRT[44], FATHMM[45], PROVEAN[46], MetaSVM[47],

MetaLR[47], PrimateAI[48], DEOGEN2[49], and MutationAssessor[50]) available through dbNSFP

database, and (3) "missense lenient", which included missense variants predicted to be

deleterious by at least seven out of the nine deleteriousness prediction tools. All UKB analyses

were performed in the DNANexus UKB RAP.

We also analyzed whole genome sequencing data of 245,388 individuals in the All of Us

(AoU) cohort. Variant call files for regions overlapping with the exomes were available as a Hail

matrix table in the AoU portal. After filtering the variants for intracohort frequency (<0.001), we

annotated the variants using Nirvana[51], available in the AoU research platform as a Hail table,

and determined the functional impact of each variant using the same criteria as defined for the

UKB data. All AoU analyses were performed in the Researcher Workbench of the AoU portal.

**Phenotype, obesogenic lifestyle, polygenic risk analyses**

***For the UKB cohort***, BMI, genetic sex (Data Field 22001), age (Data Field 21003), ethnic

background (Data Field 21000), PGS (Data Field 26216), genetic kinship (Data Field 22021),

and the top 40 genetic principal components (PCs; Data Field 22009) on 502,368 individuals in

UKB were accessed and preprocessed through the UKB RAP. Numerical fields such as BMI and

age, measured across multiple visits, were averaged. Categorical fields such as sex and ethnic

background were searched for inconsistent readings, and samples with conflicting values across

multiple assessments were dropped. We further filtered samples with 10 or more third-degree

relatives from our analysis based on previously published kinship estimates[14]. We finally divided

the cohort into two populations, based on their ethnic background namely, "British" consisting of

419,228 individuals self-reported to be "White British" based on the UKB data-field 21000, and

the other 68,070 individuals who we categorized as "non-British" population. We note that the

UKB non-British population contains individuals of European ancestry, *for example*, individuals

with self-reported "Irish" ethnic background. ***Obesogenic lifestyle factors*** such as Metabolic

Equivalent Task (MET) scores, sleep duration, alcohol consumption, or smoking habits were

also accessed and preprocessed through the UKB RAP. Numerical fields were averaged and

samples with categorical fields having conflicting values across multiple assessments were

dropped. All fields were then binarized based on their extreme values and their potential effect

on BMI as follows: Numerical fields with the potential to have a directly proportional effect on

BMI, such as "time spent watching television", were assigned as 1 for an individual, if their

corresponding value was greater than 95% quantile. On the other hand, fields with inversely

proportional effect on BMI, such as "consumption of cooked vegetable", were assigned as 1 if

the value was less than 5% quantile. Individuals with extreme values from ordinal fields that

potentially lead to increased BMI were assigned as 1, and individuals with all other values were

assigned as 0. *For example*, individuals who consumed alcohol daily or almost daily, the extreme

category for this field, were encoded as 1 for that lifestyle factor. A full description of the

lifestyle factors used in this study and the thresholds or categories used to binarize them is

available in **Supplementary Table 16**. After binarizing, the fields were combined to define one

of the six lifestyle factors, namely, (i) physical activity, (ii) alcohol, (iii) smoke, (iv) diet, (v)

sleep, and (vi) sedentary lifestyle, used in this study. Binarized MET scores, alcohol

consumption frequency, and sleep patterns were directly used as indicators of physical activity,

alcohol, and sleep metrics, respectively. Individuals whose current or past smoking tendencies

were high were considered to have the "smoke" lifestyle. Similarly, those spending more time on

TV or computer were indicative of "sedentary lifestyle". Diet was denoted as 1 if either the sum

of high processed meat-, beef-, mutton-, and pork-intake binarized columns was greater than 0,

or the sum of low cooked vegetable, salad, fresh fruit, dried fruit, oily fish, or non-oily fish-

intake binarized columns was greater than 1. Thus, the diet field used in the study is analogous to

high-meat and/or low vegetable consumption. International Classification of Disease (ICD-10)

10th revision summary diagnosis codes corresponding to each individual were also extracted

from the Hospital Episode Statistics (HES) data available in the UKB RAP.

***For the AoU cohort***, we obtained BMI, age, genetic sex, previously calculated genetic

ancestry[15], 16 genetic PCs, and sample IDs of related individuals from the AoU Workbench. We

calculated the age based on the date of birth and the BMI measurement data concepts ("concept"

defined here as a collection of similar data stored together) available in AoU. We used the "sex

at birth" concept, available in AoU, to denote the genetic sex of an individual. Only individuals

with BMI values between 12 and 75 kg/m$^2$ and "sex at birth" field listed as either "Male" or

"Female" were included to ensure consistency between UKB and AoU. Based on the predicted

genetic ancestry, we divided the AoU data into three populations namely, (1) European

(N=127,644), which included individuals predicted to be of European ancestry, (2) African

(N=54,865), which included individuals predicted to be of African ancestry, and (3) Mixed

(N=52,134), which included individuals predicted to be of Admixed American ancestry and

other ancestries. ***We calculated PGS for BMI in individuals from AoU*** by using the GWAS

summary statistics from a previous study[4]. Duplicate and ambiguous single nucleotide

polymorphism (SNPs) were filtered from the summary statistics. Genotype data of the AoU

cohort filtered for common variants (MAF>0.01) was obtained as a Hail matrix table. We further

removed variants with Hardy-Weinberg Equilibrium p-value $<1\times10^{-6}$ and retained variants that

overlapped between summary statistics data and the AoU genotyped data with a call rate greater

than 0.9. We then used the predetermined effect sizes of the SNPs as Bayesian priors, weighed

them based on the alternate allele frequency observed in individuals, and summed the weighted

effect sizes to obtain individual-specific polygenic risk for BMI. All calculations were conducted

using Hail, available in the AoU Researcher Workbench. ***Obesogenic lifestyle factors*** such as

physical activity, alcohol consumption, and smoking tendency in the AoU cohort were obtained

from survey questionnaires available through the AoU research portal. Individuals falling in the

extreme categories for each of the three factors, (1) Physical activity: "General Physical Health:

Fair" or "General Physical Health: Poor", (2) Alcohol consumption, "Drink Frequency Past

Year: 4 or More Per Week", and (3) Smoking tendency: "Smoke Frequency: Every Day", were

annotated as 1, denoting those carrying the respective obesogenic factor, while others not falling

in these extreme categories were annotated as 0. We note that physical activity measurements in
AoU were not equivalent to those in UKB, where a more rigorous assessment of an individual's
physical health was measured using International Physical Activity Questionnaire guidelines.
Additionally, diet and sedentary lifestyle information was not available in AoU, while sleep data
were available on less than 10% of the cohort and these lifestyle factors could not be tested in
AoU. ICD-10 diagnosis codes corresponding to each individual in the AoU cohort was extracted
using the researcher workbench.
491

**Gene burden association test using REGENIE**
We used REGENIE v3.3[16] to conduct gene burden association tests. Similar to most whole
genome regression tools, REGENIE operates in two steps. *First*, it uses SNP data, preferably a
genotyped array of SNPs, from across the genome to fit a null model that estimates a polygenic
score for the trait to be tested (i.e., BMI in our study). This step accounts for population structure
and relatedness between samples. For both UKB and AoU cohorts, we used the genotyped SNP
array files available in DNANexus or Researcher workbench for this step. We lifted over the
SNP array files in UKB from version hg19 to hg38 using Picard's LiftoverVCF tool[52]. In the
*second* step, REGENIE then calculates the association between the genetic variants of interest
and the trait after considering the null model calculated in step 1 and other user defined
covariates. In our study, we used age, genetic sex, and first ten genetic PCs obtained from both
UKB and AoU cohorts as additional covariates. REGENIE is capable of collapsing variants to a
gene-level with user defined masks and annotation files apart from the usual variant data as input
before running association tests. We supplied our already annotated variant file based on their
impact on gene transcripts and defined three variant masks to collapse variants on a gene level,
namely, (a) "lof" variants only, (b) "lof" and "missense strict" variants, and (c) "lof", "missense
strict" and "missense lenient" variants. We performed gene-based association tests for all the five
defined populations across both biobanks and generated statistics for all individual gene-mask
pairs.
511

**Meta analysis and variance calculation**
We first created three meta populations from the previously defined five populations (UKB
British, UKB non-British, AoU European, AoU African, and AoU Mixed), the first composed of

individuals from European ancestry (UKB British and AoU European) termed "European meta",

the second from non-European ancestry (UKB non-British, AoU African and AoU Mixed)

termed "non-European meta", and the third from all five populations termed "combined meta".

We note that a minority of individuals (approximately 15%) in the non-European population

were from ethnic groups such as 'Irish' or 'any other white background', and are therefore likely

to be of European ancestry.

Results from the individual populations were pooled into the three meta populations

using an inverse variance weighted random effects model. The meta-analysis calculation was

implemented using the python package statsmodels v0.14.2. Each gene-variant mask was

associated with meta statistics for three meta populations. Any gene-variant mask that passed the

Bonferroni multiple testing correction threshold of $8.34 \times 10^{-7}$, accounting for 20,000 genes and

three variant collapsing models, *either* in the European meta *or* the non-European meta *and* in

the combined meta population were considered to be significantly associated with BMI across

ancestries.

We calculated the interpopulation variance in effect sizes across populations for the

discovered genes passing our multiple testing criterion, as well as previously associated BMI

genes, using the "var" method available in the python package, pandas v2.1.1.

**Odds-ratio calculation for obesity clinical categories and obesity-related disorders**

To calculate risk across the obesity clinical categories among carriers of PTVs in the discovered

genes compared to non-carriers, we first categorized each individual into their respective clinical

category based on their BMI values: underweight or normal (<25), overweight (25 to 30), obese

(30 to 40) and severely obese (>40). We then created 2x2 contingency tables using their carrier

status as the first variable and whether they belong to the respective obesity category as opposed

to any other category as the second variable. Finally, we calculated the conditional odds ratio and

the significance value using a two-sided Fisher's exact test.

To calculate risk for obesity related disorders, we obtained the specific ICD codes for

comorbidities frequently associated with obesity based on previous BMI related studies and

calculated the odds of PTV carriers diagnosed with the comorbidity compared to non-carriers

using Fisher's exact test. A list of the comorbidities and the ICD codes used to categorize an

individual as carrying the comorbidity is provided in **Supplementary Table 17**. All odds ratio

calculations were conducted using the scipy v1.11.3 package available in python.

**Functional analysis of the discovered genes**

We overlapped the list of discovered genes with a BMI gene list obtained from the GWAS

catalogue[19], where the SNPs identified in previous BMI GWAS studies are mapped to their most

likely gene targets. We further overlapped the discovered gene list with gene phenotype

associations from Common Metabolic Diseases Knowledge Portal (CMDKP) database[20].

CMDKP aggregates information and scores genotype-phenotype relationships (Human Genetic

Evidence or HuGE scores[21]) based on the evidence acquired from previous rare and common

variant association studies for all common metabolic disorders, including obesity and related

phenotypes. Any gene that showed strong associations (HuGE score≥10, indicating "strong"

evidence of gene-phenotype link) with obesity, BMI, or related phenotypes, such as fasting

insulin adjusted BMI, or waist hip ratio adjusted BMI, were considered an overlapping BMI

related gene. Associations of the discovered genes with previous *in vivo* studies of knockout

(KO) mouse models were first identified using data from the International Mouse Phenotyping

Consortium (IMPC)[22], which provides comprehensive phenotypic characterization of mouse

KOs, including assessments of body weight and obesity-related traits. IMPC represents an

unbiased resource for investigating the *in vivo* effects of novel genes that have not been studied

in the context of obesity. Further, we conducted a PubMed search of each gene by searching for

the gene name in the abstract or title and "obesity" in the text. This provided additional

functional evidence for the novel genes, which have been phenotypically characterized using

mouse models, or other complementary approaches such as human genetic studies. The BMI-

associated GWAS gene list was directly obtained from NHGRI-EBI catalog, while associations

from CMDKP, IMPC, and PubMed were accessed programmatically through their REST API

using python's requests v2.31.0 module.

**Proteomics data analysis of oligogenic combinations**

Normalized plasma protein expression data of 1,463 proteins on 50,956 individuals were

accessed through the DNANexus portal of UKB RAP. Multiple replicates of protein readouts

were averaged, and protein levels of corresponding genes were identified. Using linear

regression models, the effect of protein expression levels for the discovered genes with available

protein data on BMI was measured, while accounting for covariates such as age, genetic sex, ten

genetic PCs, PGS, and the interaction term between the protein and the PGS. The model was

trained using "ols" function from statsmodels v0.14.2 package available in python.

**Interaction models for obesity risk factors**

To assess interactive effects between each gene and PGS, we used a linear regression model to

predict BMI using individual as well as interactive terms between PGS and PTV carrier status

for the discovered genes while accounting for age, genetic sex, and ten genetic PCs. We obtained

separate model coefficients in UKB and AoU cohorts and then used random effect meta-analysis

to combine the statistics from the two cohorts. Interaction terms with meta-analysis $P$ value less

than 0.05 were considered significant gene-PGS interactions. The models were trained using

"ols" function from statsmodels v0.14.2 package, available in python.

589            To compare interactive effects between lifestyle factors and gene PTV carrier status, we

conducted factorial analysis of covariance using the individual gene and lifestyle terms as well as

the gene-lifestyle interaction term, while accounting for age, genetic sex, first ten genetic PCs

and PGS, separately in UKB and AoU cohorts. Interaction terms that crossed the $P$ value

threshold (0.05) in both UKB and AoU were considered significant gene-lifestyle interactions.

Model training and calculation of $P$ value significance and confidence intervals were performed

using "ols" and "anova_lm" function from statsmodels v0.14.2 package available in python.

**AUTHOR CONTRIBUTIONS**

S.G and D.B conceived the study, acquired, analyzed and interpreted the data, and wrote the

manuscript.

**ACKNOWLEDGEMENTS**

We thank Corrine Smolen and Jiawan Sun for critical reading of the manuscript. We thank the

participants and investigators in the UK Biobank and All of US research studies who made this

work possible. This research has been conducted using the UK Biobank Resource under

Application Number 45023. We also thank the National Institutes of Health's All of Us Research

Program for making available the participant data examined in this study. This work was

supported by NIH R01-GM121907, resources from the Huck Institutes of the Life Sciences and

the Pennsylvania State University to S.G. The authors declare no competing interests.

**Data and code availability**

The UK Biobank and All of Us genetic and phenotypic data analyzed in this study are publicly

available to registered researchers through their respective analysis portals. Additional

information about registration for access to the data is available at https://www.ukbiobank.ac.uk/

and https://www.researchallofus.org/ for UK Biobank and All of Us, respectively. The code for

pre-processing, filtering, annotating genetic data, association tests and statistical analysis is

available on GitHub (https://github.com/deeprob/BMI_monogenic).

**REFERENCES**

1.  Kivimäki, M. *et al.* Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. *Lancet Diabetes Endocrinol* **10**, 253–263 (2022).

2.  Kilpeläinen, T. O. *et al.* Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. *PLoS Med* **8**, e1001116 (2011).

3.  Kim, M. S. *et al.* Association of genetic risk, lifestyle, and their interaction with obesity and obesity-related morbidities. *Cell Metab* **36**, 1494-1503.e3 (2024).

4.  Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197–206 (2015).

5.  Khera, A. V. *et al.* Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. *Cell* **177**, 587-596.e9 (2019).

6.  Turcot, V. *et al.* Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. *Nat Genet* **50**, 26–41 (2018).

7.  Zhao, Y. *et al.* Protein-truncating variants in BSN are associated with severe adult-onset obesity, type 2 diabetes and fatty liver disease. *Nat Genet* **56**, 579–584 (2024).

8.  Zhu, N. *et al.* Rare predicted loss of function alleles in Bassoon (BSN) are associated with obesity. *NPJ Genom Med* **8**, 33 (2023).

9.  Akbari, P. *et al.* Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. *Science* **373**, eabf8683 (2021).

10. Fatumo, S. *et al.* A roadmap to increase diversity in genomic studies. *Nat Med* **28**, 243–250 (2022).

11. Cohen, J. *et al.* Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. *Nat Genet* **37**, 161–165 (2005).

12. Genovese, G. *et al.* A risk allele for focal segmental glomerulosclerosis in African

Americans is located within a region containing APOL1 and MYH9. *Kidney Int* **78**, 698–704

(2010).

13. Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic

Studies. *Cell* **177**, 1080 (2019).

14. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

*Nature* **562**, 203–209 (2018).

15. All of Us Research Program Genomics Investigators. Genomic data in the All of Us

Research Program. *Nature* **627**, 340–346 (2024).

16. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and

binary traits. *Nat Genet* **53**, 1097–1103 (2021).

17. Paule, R. C. & Mandel, J. Consensus Values and Weighting Factors. *J Res Natl Bur Stand*

*(1977)* **87**, 377–385 (1982).

18. Kaisinger, L. R. *et al.* Large-scale exome sequence analysis identifies sex- and age-specific

determinants of obesity. *Cell Genom* **3**, 100362 (2023).

19. Sollis, E. *et al.* The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource.

*Nucleic Acids Res* **51**, D977–D985 (2023).

20. Common Metabolic Diseases Knowledge Portal (cmdkp.org); (RRID:SCR_020937).

21. Dornbos, P. *et al.* Evaluating human genetic support for hypothesized metabolic disease

genes. *Cell Metab* **34**, 661–666 (2022).

22. International Mouse Phenotyping Consortium.

23. Li, P. *et al.* Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances

PPARγ activity and insulin sensitivity. *Cell* **147**, 815–826 (2011).

24. Sa, M. *et al.* Hypothalamic GABRA5-positive neurons control obesity via astrocytic GABA.

*Nat Metab* **5**, 1506–1525 (2023).

25. Li, H. *et al.* FGF2 disruption enhances thermogenesis in brown and beige fat to protect

against adiposity and hepatic steatosis. *Mol Metab* **54**, 101358 (2021).

26. de Haan, W., Bhattacharjee, A., Ruddle, P., Kang, M. H. & Hayden, M. R. ABCA1 in

adipocytes regulates adipose tissue lipid content, glucose tolerance, and insulin sensitivity. *J*

*Lipid Res* **55**, 516–523 (2014).

27. Cheng, X. *et al.* Ablation of promyelocytic leukemia protein (PML) re-patterns energy

balance and protects mice from obesity induced by a Western diet. *J Biol Chem* **288**, 29746–

29759 (2013).

28. Diaz-Vegas, A. *et al.* Deletion of miPEP in adipocytes protects against obesity and insulin

resistance by boosting muscle metabolism. *Mol Metab* **86**, 101983 (2024).

29. An, Y. A. *et al.* Angiopoietin-2 in white adipose tissue improves metabolic homeostasis

through enhanced angiogenesis. *Elife* **6**, e24071 (2017).

30. Patitucci, C. *et al.* Mtfp1 ablation enhances mitochondrial respiration and protects against

hepatic steatosis. *Nat Commun* **14**, 8474 (2023).

31. Jurgens, S. J. *et al.* Rare coding variant analysis for human diseases across biobanks and

ancestries. *Nat Genet* **56**, 1811–1820 (2024).

32. Meyer-Schaller, N. *et al.* The human Dcn1-like protein DCNL3 promotes Cul3 neddylation

at membranes. *Proc Natl Acad Sci U S A* **106**, 12365–12370 (2009).

33. Monda, J. K. *et al.* Structural conservation of distinctive N-terminal acetylation-dependent

interactions across a family of mammalian NEDD8 ligation enzymes. *Structure* **21**, 42–53

(2013).

34. Yu, M. *et al.* Emerging role of NEDD8-mediated neddylation in age-related metabolic

diseases. *Ageing Res Rev* **94**, 102191 (2024).

35. Zhang, S., Yu, Q., Li, Z., Zhao, Y. & Sun, Y. Protein neddylation and its role in health and

diseases. *Signal Transduct Target Ther* **9**, 85 (2024).

36. Madeira, A., Moura, T. F. & Soveral, G. Aquaglyceroporins: implications in adipose biology

and obesity. *Cell Mol Life Sci* **72**, 759–771 (2015).

37. Cannon, M. *et al.* DGIdb 5.0: rebuilding the drug-gene interaction database for precision

medicine and drug discovery platforms. *Nucleic Acids Res* **52**, D1227–D1235 (2024).

38. Ni, B. *et al.* Selective adipocyte loss of Angiopoietin-2 prompts female-specific obesity and

metabolic syndrome. *Mol Metab* **65**, 101588 (2022).

39. Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank participants.

*Nature* **599**, 628–634 (2021).

40. Hail Team. Hail 0.2. (https://github.com/hail-is/hail).

41. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122 (2016).

42. Liu, X., Li, C., Mou, C., Dong, Y. & Tu, Y. dbNSFP v4: a comprehensive database of

transcript-specific functional predictions and annotations for human nonsynonymous and

splice-site SNVs. *Genome Med* **12**, 103 (2020).

43. Ng, P. C. & Henikoff, S. Predicting deleterious amino acid substitutions. *Genome Res* **11**,

863–874 (2001).

44. Chun, S. & Fay, J. C. Identification of deleterious mutations within three human genomes.

*Genome Res* **19**, 1553–1561 (2009).

45. Shihab, H. A. *et al.* Predicting the functional, molecular, and phenotypic consequences of

amino acid substitutions using hidden Markov models. *Hum Mutat* **34**, 57–65 (2013).

46. Choi, Y., Sims, G. E., Murphy, S., Miller, J. R. & Chan, A. P. Predicting the functional effect

of amino acid substitutions and indels. *PLoS One* **7**, e46688 (2012).

47. Dong, C. *et al.* Comparison and integration of deleteriousness prediction methods for

nonsynonymous SNVs in whole exome sequencing studies. *Hum Mol Genet* **24**, 2125–2137

(2015).

48. Sundaram, L. *et al.* Predicting the clinical impact of human mutation with deep neural

networks. *Nat Genet* **50**, 1161–1170 (2018).

49. Raimondi, D. *et al.* DEOGEN2: prediction and interactive visualization of single amino acid

variant deleteriousness in human proteins. *Nucleic Acids Res* **45**, W201–W206 (2017).

50. Reva, B., Antipin, Y. & Sander, C. Predicting the functional impact of protein mutations:

application to cancer genomics. *Nucleic Acids Res* **39**, e118 (2011).

51. Stromberg, M. *et al.* Nirvana: Clinical Grade Variant Annotator. in *Proceedings of the 8th*

*ACM International Conference on Bioinformatics, Computational Biology,and Health*

*Informatics* 596–596 (ACM, Boston Massachusetts USA, 2017).

doi:10.1145/3107411.3108204.

52. Picard (http://broadinstitute.github.io/picard/).